The scrutiny follows the company’s August 5, 2026, financial report for the quarter ending June 30. Emergent disclosed a $191.3 million non-cash impairment charge linked to its NARCAN asset group, resulting in a GAAP net loss of $180.2 million. Alongside these losses, management slashed its full-year revenue outlook by approximately 10.8%, citing heightened market competition that threatened the book value of its key assets.

Investors reacted sharply to the disclosure, driving shares down $2.23 to close at $5.31 on August 6. Pomerantz LLP is now seeking contact from shareholders affected by this volatility. Danielle Peyton is handling inquiries regarding the firm's evaluation of potential corporate misconduct or breaches of fiduciary duty.